BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20576051)

  • 1. Development of factor V and thrombin inhibitors in children following bovine thrombin exposure during cardiac surgery: a report of three cases.
    Bomgaars L; Carberry K; Fraser C; West A; Teruya J
    Congenit Heart Dis; 2010; 5(3):303-8. PubMed ID: 20576051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
    Savage WJ; Kickler TS; Takemoto CM
    Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
    Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
    J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin.
    Lo CY; Jones C; Glader B; Zehnder JL
    Pediatr Blood Cancer; 2010 Dec; 55(6):1195-7. PubMed ID: 20979176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases.
    Poynton AR; Nelson MC; McCance SE; Levine RL; O'Leary PF
    Spine (Phila Pa 1976); 2003 Jun; 28(12):E221-3. PubMed ID: 12811284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report.
    Adams JD; Jones S; Brost BC
    J Reprod Med; 2001 Oct; 46(10):909-12. PubMed ID: 11725736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency.
    Cmolik BL; Spero JA; Magovern GJ; Clark RE
    J Thorac Cardiovasc Surg; 1993 Feb; 105(2):222-7; discussion 227-8. PubMed ID: 8429648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired inhibitors to factors V and X after exposure to topical thrombin: interference with monitoring of low molecular weight heparin and warfarin.
    Israels SJ; Leaker MT
    J Pediatr; 1997 Sep; 131(3):480-3. PubMed ID: 9329435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bovine thrombin: history, use, and risk in the surgical patient.
    Diesen DL; Lawson JH
    Vascular; 2008; 16 Suppl 1():S29-36. PubMed ID: 18544303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
    Caers J; Reekmans A; Jochmans K; Naegels S; Mana F; Urbain D; Reynaert H
    Endoscopy; 2003 Jun; 35(6):542-4. PubMed ID: 12783357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin.
    Muntean W; Zenz W; Edlinger G; Beitzke A
    Thromb Haemost; 1997 Jun; 77(6):1223. PubMed ID: 9241765
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of rituximab therapy in patients with acquired factor V inhibitors.
    Navarrete MA; van der Meer FJ; Damiani G; Diaz A; Eikenboom J
    Am J Hematol; 2012 Aug; 87(8):826-7. PubMed ID: 22641484
    [No Abstract]   [Full Text] [Related]  

  • 13. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin.
    Crow SS; Sullivan VV; Aysola AE; Key NS; Harker-Murray P; Foker JE; Steiner ME
    Ann Thorac Surg; 2007 Apr; 83(4):1547-9. PubMed ID: 17383385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-mediated coagulopathy: a case report.
    Naoum JJ
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):13S-7S. PubMed ID: 19558280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter pilot study to estimate the prevalence of bovine and human coagulation antibodies in the general US population.
    Fareed J; Paterson CA; Crean SM
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):164-70. PubMed ID: 21078614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe coagulopathy following intraoperative use of topical thrombin.
    Sarfati MR; Dilorenzo DJ; Kraiss LW; Galt SW
    Ann Vasc Surg; 2004 May; 18(3):349-51. PubMed ID: 15354638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases.
    Spero JA
    J Neurosurg; 1993 May; 78(5):817-20. PubMed ID: 8468613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with intravenous immunoglobulin (IVIg) in a patient with an acquired factor V inhibitor after liver transplantation.
    Guglielmone H; Jarchum G; Minoldo S
    Thromb Haemost; 2011 Nov; 106(5):985-6. PubMed ID: 21901236
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin.
    Israels SJ; Israels ED
    Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):249-54. PubMed ID: 8037345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-mediated coagulopathy associated with topical bovine thrombin: review of the pediatric literature.
    Rodgers GM
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):86-8. PubMed ID: 21228719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.